Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNK-2726
- Development stage
- Unknown
- Lead developer
- SynerK PharmaTech
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SNK-2726 is a long-acting small interfering RNA (siRNA) therapeutic developed by SynerK PharmaTech in collaboration with Huadong Medicine for the treatment of hypertension. It is designed to target and silence the messenger RNA (mRNA) of angiotensinogen (AGT) in the liver. AGT is the sole precursor of all angiotensin peptides in the renin-angiotensin-aldosterone system (RAAS), which plays a central role in blood pressure regulation. By potently inhibiting the synthesis of AGT, SNK-2726 prevents the activation of the RAAS, leading to a stable and continuous decrease in blood pressure. The drug is administered via subcutaneous injection and is currently in Phase I clinical development.
02
Targets
AGT (O6-methylguanine-DNA methyltransferase)
Beyond the preview
Go deeper on SNK-2726.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNK-2726.